Poultry Vaccine - Necrotic Enteritis

Opportunity

Our experimental vaccine is composed of three novel antigens from the pili of Clostridium perfringens, the causative agent of necrotic enteritis (NE) in poultry.  NE costs the global poultry industry US $5-6B annually, or $0.05-$0.15 per chick sold and as regulations eliminate the use of antibiotics in feed, these costs will rise significantly. Challenge studies have confirmed moderate efficacy and immunogenicity resulting in partial protection of vaccinated birds in a severe challenge model. The vaccine created by Drs. Joshua Gong, Dion Lepp at Agriculture and Agri-Food Canada and Dr. John Prescott at the University of Guelph disrupts the ability of the  bacteria to attach to the gut wall to colonize. These three new antigens may be useful in the development of an improved multi-antigen vaccine, when combined with the best known protective antigens to date.  

Potential Markets

Intensified poultry production – especially broilers 

Status

  • Technology Readiness Level 3
  • Preliminary vaccine tested in poultry 
  • Seeking additional industry and academic partners to collaborate with the University of Guelph and Agriculture & Agri-food Canada.
  • Additional antigens needed to improve efficacy

Patent Status

US provisional patent filed

License Status

Unlicensed 

Contacts

David Hobson, dhobson@uoguelph.ca 519-824-4120 x58859
Horst Donner, horst.donner@agr.gc.ca 226-217-8099